Cargando…
Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high morbidity and limited treatment options. Type 2 diabetes mellitus (T2DM) is a common comorbid illness among patients with IPF and is often treated with metformin, the first-line agent in the management of...
Autores principales: | Teague, Taylor T., Payne, Stephanie R., Kelly, Bryan T., Dempsey, Timothy M., McCoy, Rozalina G., Sangaralingham, Lindsey R., Limper, Andrew H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004115/ https://www.ncbi.nlm.nih.gov/pubmed/35410255 http://dx.doi.org/10.1186/s12931-022-02001-0 |
Ejemplares similares
-
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
por: Kelly, Bryan T., et al.
Publicado: (2021) -
Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment
por: Herberts, Michelle B., et al.
Publicado: (2023) -
Reply: Adoption of Antifibrotic Medications: A Closer Look at the Data
por: Dempsey, Timothy M., et al.
Publicado: (2021) -
Association of Area-Level Socioeconomic Deprivation With Hypoglycemic and Hyperglycemic Crises in US Adults With Diabetes
por: Kurani, Shaheen Shiraz, et al.
Publicado: (2022) -
The Added Power of Synthetic Control Groups: Challenging Conventional Wisdom and Trial Design in Idiopathic Pulmonary Fibrosis Research
por: Dempsey, Timothy M., et al.
Publicado: (2023)